Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study
Language English Country Germany Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antidepressive Agents, Tricyclic therapeutic use MeSH
- Body Mass Index MeSH
- Humans MeSH
- Anorexia Nervosa drug therapy psychology MeSH
- Mianserin analogs & derivatives therapeutic use MeSH
- Mirtazapine MeSH
- Adolescent MeSH
- Drug Administration Schedule MeSH
- Case-Control Studies MeSH
- Check Tag
- Humans MeSH
- Adolescent MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antidepressive Agents, Tricyclic MeSH
- Mianserin MeSH
- Mirtazapine MeSH
OBJECTIVE: Anorexia nervosa (AN) is a serious and potentially life-threatening psychiatric disorder. Pharmacotherapeutic possibilities still remain limited. We sought to determine if there was a positive effect on body weight and body mass index (BMI) in AN patients being treated for depression or anxiety with mirtazapine. METHODS: Using a case-control design, we found nine female patients with AN who had been treated with mirtazapine for depression or anxiety during hospitalization in our department. We also found nine female controls with AN, who had not received any pharmacotherapy. The two groups of patients were matched according to age and BMI. Case and control groups did not differ significantly in age (15.2 +/- 1.9 Vs. 14.7 +/- 1.7 years; P = 0.549), or in BMI (15.6 +/- 2.3 Vs. 15.6 +/- 2.1; P = 0.946) at baseline. Weight and BMI were evaluated at baseline and again after the patients had completed 1, 2, 3 and 4 weeks of treatment. RESULTS: The mean dose of mirtazapine was 21.7 +/- 1.8 mg at the end of week 4. Using ANOVA Repeated Measures, we found no significant differences between cases and controls with regard to weight (P = 0.981) or BMI (P = 0.576). However, there was a non-significant trend in patients which had been treated with mirtazapine which showed slightly more improvement, in the measured parameters, at the end of weeks 1, 2 and 3, compared to controls. CONCLUSION: Results are limited by small sample size. However, the use of mirtazapine could be useful in the treatment of AN in adolescence.
See more in PubMed
Int J Psychiatry Clin Pract. 1997;1(1):21-35 PubMed
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):306-9 PubMed
World Psychiatry. 2005 Jun;4(2):69-73 PubMed
Int J Clin Pharmacol Ther. 2006 Sep;44(9):452-3 PubMed
Int J Eat Disord. 2005;37 Suppl:S60-3; discussion S87-9 PubMed
